Wedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Equities research analysts at Wedbush lowered their Q2 2025 earnings per share (EPS) estimates for Xencor in a report released on Wednesday, May 7th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.60). Wedbush has a "Outperform" rating and a $31.00 price target on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor's Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.03) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.80) EPS, FY2026 earnings at ($3.20) EPS, FY2027 earnings at ($3.39) EPS, FY2028 earnings at ($4.29) EPS and FY2029 earnings at ($5.95) EPS.

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Company reduced their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. William Blair assumed coverage on shares of Xencor in a report on Monday, April 21st. They set an "outperform" rating for the company. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, Barclays lowered their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $29.50.

Xencor Trading Down 1.2%

Shares of NASDAQ:XNCR traded down $0.10 during midday trading on Monday, hitting $8.10. The company had a trading volume of 82,184 shares, compared to its average volume of 646,337. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor has a 12 month low of $7.16 and a 12 month high of $27.24. The firm has a fifty day simple moving average of $10.29 and a 200 day simple moving average of $17.30. The stock has a market cap of $576.33 million, a price-to-earnings ratio of -2.53 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). The business had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company's quarterly revenue was up 104.6% on a year-over-year basis. During the same period last year, the firm earned ($1.11) earnings per share.

Hedge Funds Weigh In On Xencor

Several institutional investors and hedge funds have recently modified their holdings of XNCR. GAMMA Investing LLC lifted its stake in shares of Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 508 shares during the last quarter. KBC Group NV raised its holdings in Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 813 shares during the period. Sterling Capital Management LLC lifted its position in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,040 shares during the last quarter. New York State Teachers Retirement System boosted its holdings in shares of Xencor by 2.1% during the first quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock worth $631,000 after acquiring an additional 1,200 shares during the period. Finally, Summit Investment Advisors Inc. grew its position in shares of Xencor by 22.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock valued at $162,000 after purchasing an additional 1,282 shares during the last quarter.

Insiders Place Their Bets

In other news, EVP Nancy Valente sold 4,616 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares of the company's stock, valued at $542,334.07. This trade represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.76% of the company's stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.